Several studies have reported that Naringin can upregulate the expression of Caspase-3, cleaved Caspase-3 and Bax in thyroid cancer TPC-1 and SW1736 (Zhou et al., 2019), glioma U87 (Wei et al., 2020), and gastric cancer SUN-1 cell (Xu et al., 2021), and downregulate the expression of survivin and Bcl-2, thereby inducing cell apoptosis, by inhibiting the activation of PI3K/AKT pathway. Here, BCL2 is linked to thyroid gland carcinoma.